Pharmaceutical patent expropriation and technology strategy: Strategic options to compulsory licensing

Technology Analysis and Strategic Management

Volumn 22, Issue 1, 2010, Pages 19-41

  Hemphill, Thomas A ^a  

^a UNIVERSITY OF MICHIGAN FLINT   (United States)

Author keywords

Compulsory licensing; Parallel importing; Patents; Pharmaceutical industry; Technology strategy

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ECONOMIC STRUCTURE; GLOBAL PERSPECTIVE; HUMAN IMMUNODEFICIENCY VIRUS; INTELLECTUAL PROPERTY RIGHTS; PHARMACEUTICAL INDUSTRY; STRATEGIC APPROACH; TECHNOLOGY POLICY; WORLD TRADE ORGANIZATION;

SOUTH AMERICA; SOUTHEAST ASIA; SUB-SAHARAN AFRICA;

EID: 74949132285     PISSN: 09537325     EISSN: 14653990     Source Type: Journal    
DOI: 10.1080/09537320903438039     Document Type: Article

References (79)

1. Adler, P. 1989. Technology strategy: a guide to the literature. In Research on technological innovation, management and policy, ed. R.A. Burgelman and R.S. Rosenbloom, 125-51. Greenwich, CT: JAI Press.
2. Alcorn, K. 2007. Brazil issues compulsory license on Efavirenz. National Association of Manufacturers (7 May). http://www.aidsmap. com/en/news/0550CE62-3F90-4603-932C-EF69E1B4485D.asp?type (accessed 7 May 2007).
3. Attaran, A. 2004. How do patents and economic policies affect essential medicines in developing countries? Health Affairs 23, no. 3: 155-66.
4. Attaran, A., and L. Gillespie-White. 2001. Do patents for antiretroviral drugs constrain access toAIDS treatment inAfrica? Journal of the American Medical Association 286, no. 15: 1886-92.
5. Baker, B.K. 2005. India's 2005 patent law: death by patent or universal access to second- and future-generation ARVs? HealthGap: Global Access Project (Background Paper), 19 September. http://www.healthgap.org/press_releases/05/ 091905_HGAP_BP_India_patent_baker.html (accessed 8 November 2007).
6. Batson, A. 2001. Understanding the vaccine market and its economics. Presentation to the Out of the Box Group, 26 July. www.vaccinealliance.org/site_repository/resources/21VacMarket.pdf (accessed 27 June 2007).
7. Boseley, S. and R. Carroll. 2002. Profiteers resell Africa's cheap AIDS drugs. The Guardian, 3 October. http://www. buzzle.com/editorials/10-3-2002-27507.asap (accessed 25 July 2007).
8. Bulletin of the World Health Organization. 2006.Access toAIDS medicines stumbles on trade rules. Bulletin of the World Health Organization 84, no. 5: 342-4.
9. Burgelman, R.A., and R.S. Rosenbloom. 1989. Technology strategy: an evolutionary process perspective. In Research on technological innovation, management and policy. Ed. R.A. Burgelman and R.S. Rosenbloom, 1-23. Greenwich, CT: JAI Press.
10. Center for Global Development. 2005. Making markets for vaccines: a practical plan. April, Washington, DC, p. 18.
11. Center for International Development. 2006. UK chancellor Gordon Brown announces vaccine purchase commit-ments for HIV/AIDS and malaria. Harvard University (31 July). http://www.cid.harvard.edu/books/kremer04_ strongmedicine.html (accessed 22 May 2007).
12. Chesbrough, H. 2003. The logic of open innovation: managing intellectual property. California Management Review 45, no. 3: 33-58.
13. Children's Vaccine Initiative. 1999. A plethora of hi-tech vaccines: Genetic, edible, sugar glass, and more. CVI Forum 18: 5-24.
14. Chu, W.L. 2006. New study reveals pharma market grew 7 pc in 2005. DrugResearcher. com (23 March). http://www. drugresearcher.com/news/ngaso?n=66620-ins-byetta-gardasll (accessed 13 June 2007).
15. CMR International. 2006. 2006/2007 Pharmaceutical R&D factbook. Philadelphia, PA: Thomson Scientific.
16. Cockburn, I.M., and R. Henderson. 2003. Survey results from the 2003 intellectual property owners association survey on strategic management of intellectual property. Intellectual Property Owners Association (October), Washington DC.
17. Cohen, J. 2007. Brazil, Thailand override big pharma patents. Science 316 (11 May): 816.
18. Cohen, W.M., R.M. Nelson, and J.P. Walsh. 2000. Protecting their intellectual assets: appropriabilty conditions and why US manufacturing firms patent (or not). National Bureau of Economic Research Working Paper No. 7495.
19. Cohen, W.M. 2002. Patents: their effectiveness and role. Presentation Prepared for the FTC/DOJ Hearings on Com-petition and Intellectual Property Law in the Knowledge-Based Economy (20 February), Washington, DC, USA. http://www.ftc.gov/opp/intellect/cohen.pdf (accessed 13 July 2007).
20. Congressional Budget Office. 2006. Research and development in the pharmaceutical industry. Congress of the United States (October), Washington, DC.
21. Cool, K., and D. Schendel. 1988. Performance differences among strategic group members. Strategic Management Journal 9: 207-23.
22. Cool, K., and I. Dierickx. 1993. Rivalry, strategic groups and firm profitability. Strategic Management Journal 14: 47-59.
23. Daily Herald. 2007. Brazil will ignore AIDS drug patent. Daily Herald, 5 May. www.http://www.dailyherald.com/ search/printstory.asp?id=309645 (accessed 10 May 2007).
24. Danzon, P.M., and Towse, A. 2003. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International Journal of Health Care Finance and Economics 3: 183-205.
25. D'Aveni, R.A., and R. Gunther. 1995. Hyper-competitive rivalries: competing in a highly dynamic environment. New York: The Free Press.
26. Davidson, L., and G. Greblov. 2005. The pharmaceutical industry in the global economy. Prepared for the Indiana Economic Development Corporation, with the support of the Center for International Business Education and Research at the Indiana University Kelly School of Business (Summer).
27. DiMasi, J.A., R.W. Hansen, and H.G. Grabowski. 2003. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22, no. 2: 151-85.
28. Dussauge, P., S. Hart, and B. Ramanantsoa. 1992. Strategic technology management. Chichester: John Wiley.
29. Ernst and Young LLP. 2000. Convergence: biotechnology industry report, Millennium edn. New York: Ernst and Young LLP.
30. Frank, R.G. 2003. New estimates of drug development costs. Journal of Health Economics 22, no. 2: 325-30.
31. Friedman, M.A., H. den Besten, and A. Attaran. 2003. Out-licensing: a practical approach for improvement of access to medicines in poor countries. The Lancet 361, 25 January: 341-4.
32. Gerhardsen, T.I.S. 2006. Thailand compulsory license on AIDS drug prompts policy debate. Intellectual Property Watch (22 December). http://www.ip-watch.org/weblog/index.php?p=499&print=1&res=1024&print=1 (accessed 19 June 2007).
33. Gerhardsen, T.I.S. 2007. Drug company reacts to Thai license: government ready to talk. Intellectual Property Watch (February16). http://www.ip-watch.org/weblog/index.php? p=538&print=1&res=1024&print=1 (accessed 19 June 2007).
34. Grant, R.M. 1996a. Toward a knowledge-based view of the firm. Strategic Management Journal17 (Winter Special Issue): 109-22.
35. Grant, R.M. 1996b. Prospering in dynamically competitive environments: organizational capability as knowledge integration. Organization Science 7, no. 4: 375-87.
36. Greb, E., and P. van Arnum. 2007. Pharmaceutical technology's manufacturers' rankings. Pharmaceutical Technology, 2 June. http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=428385&pageID=2 (accessed 9 June 2007).
37. Hanel, P. 2006. Intellectual property rights business management practices: a survey of the literature. Technovation 26, no. 8: 895-931.
38. Hill, C.W.L., and G.R. Jones. (2007) Strategic management: an integrated approach, 7th edn. Boston, MA: Houghton Mifflin.
39. Hrebiniak, L.G., and W.F. Joyce. 1985. Organizational adaptation: strategic choice and environmental determinism. Administrative Science Quarterly 30: 336-49.
40. innovation.org. 2007. http://www.innovation.org/index.cfm/toolsandresources/factsheets/innovation_by_the_numbers (accessed 24 June 2007).
41. Kool, K.O., and D. Schendel. 1987. Strategic group formation and performance: the case of the US pharmaceutical industry, 1963-1982. Management Science 33, no. 9: 1102-24.
42. Laesk, G., and D. Parker. 2007. Strategic groups, competitive groups and performance within the U.K. pharmaceutical industry: improving our understanding of the competitive process. Strategic Management Journal 28: 723-45.
43. Levin, R.C. 1986. New look at the patent system. American Economic Review 34: 198-203.
44. Mansfield, E., M. Schwartz, and S. Wagner. 1986. Imitation costs and patents: an empirical study. The Economic Journal 91: 907-18.
45. Maskus, R.E. 2001. Parallel imports in pharmaceuticals: implications for competition and prices in developing countries. Final report to the world intellectual property organization (April), Geneva, Switzerland.
46. Mercer Management Consulting. 2002. Lessons learned: new procurement strategies for vaccines. Final report to the GAVI Board, NewYork, NY. http://gaviftf.info/docs_activities/pdf/lessons_learned_ draft_final. pdf (accessed 27 June 2007).
47. Narayanan, V.K. 2001. Managing technology and innovation for competitive advantage. Upper Saddle River, NJ: Prentice-Hall.
48. Office of the United States Trade Representative. 2007. 2007 Special 301 Report. Washington, DC.
49. Oh, C. 2006. Compulsory licenses: recent experiences in developing countries. International Journal of Intellectual Property Management 1, no. 1/2: 22-36.
50. Pachovski, S., and L.A. Kogan. 2005. The wolf and the stork: how Brazil's breaking of U.S. drug patents threatens global trade and public health (White Paper: June 14). Institute of Trade, Standards, and Sustainable Development, Princeton, NJ.
51. Pecoul, B., P. Chirac, P. Trouiller, and J. Pinel. 1999. Access to essential drugs in poor countries. Journal of the American Medical Association 281, no. 4: 361-67.
52. PhRMA. 2007. PhRMA: Compulsory licensing trend dangerous. Press Release, 14 May 2007. http://www.phrma.org/ news_room/press_releases/phrma%3a_compulsory_licensing_trend (accessed 10 June 2007).
53. Pharmaceutical Business Review (Online). 2007. Breaking Merck patent may drive investment away from Brazil. (9 May). http://www.pharmaceutical-business-review.com/article_feature_print_asp?guid=8A869BF (accessed 19 June 2007)>.
54. Porter, M.E. 1980. Competitive strategy: techniques for analyzing industries and competitors. NewYork: The Free Press.
55. Proctor, A.R., and O.A. Schlake. 2004. Innovating strategy: a new basis for competitiveness in business and technology. ARP Consulting Inc. & Stravigant LLC (July). http://www.sheridanpark.ca/docs/Innovation_Strategy_07_2004. pdf (accessed 17 July 2007).
56. Quashigah, C. 2005. Notification of emergency and issuance of government use license (compulsory license copy). 26 October. http://www.cptech.orig/ip/health/cl/Ghana.png (accessed 10 June 2007).
57. Rader, R.A. 2005. What is a biopharmaceutical? Part 1: (Bio)technology-based definitions. BioExecutive International (March): 60-5.
58. Reitzig, M. 2004. Strategic management of intellectual property. MIT Sloan Management Review 45, no. 3: 35-40.
59. Stevens, P. 2007. Thailand violates drug patents for its own profit. Sun-Times (5 May). http://www.suntimes.com/news/otherviews/371919,CST-EDT-REF05B.articleprint (accessed 10 May 2007).
60. The Economist. 2007. A conflict of goals: helping patients, or science. (10 May). http://www.economist.com/world/la/ PrinterFriendly.cfm?story_id=9154222 (accessed 19 June 2007).
61. The Wall Street Journal. 2007. Thai flu moves south. Editorial. The Wall Street Journal, 7 May: A14.
62. UNAIDS. 2006. 2006 Report on the global AIDS epidemic. UNAIDS, NewYork, NY.
63. U.S. NAICS Manual. 2007. Pharmaceutical and medicine industry, NorthAmerican industry classification system. NAICS 3391.
64. Vasan, A., D. Hoos, J.S. Mukherjee, P.E. Farmer, A.G. Rosenfield, and J.H. Perriens. 2006. Bulletin of the World Health Organization 84, no. 5: 393-8.
65. Vepachedu, S. 2004. New patent regime in the Indian union. The Andrha Journal of Industrial News, Issue 9 (December). http://www.vepachedu.com/AJIN/ajinDecember2004.html (accessed 5 November 2007).
66. Walsh, J.P., A. Ahora, and W.M. Cohen. 2003. Working through the patent problem. Science, 299, 14 February: 1021.
67. World Health Organization. 2003a. Investing in health: a summary of the findings of the commission on macroeconomics and health. CMH Support Unit, Geneva, Switzerland.
68. World Health Organization. 2003b.The world health report 2003: shaping the future. Geneva, Switzerland.
69. World Health Organization. 2004. Equitable access to essential medicines: a framework for collective action. WHO Policy Perspectives on Medicines (Monograph) (March): 1-8, Geneva, Switzerland.
70. World Health Organization. 2005. Progress on global access to HIV antiretroviral therapy: an update on '3 by 5 (June)'. Geneva, Switzerland.
71. World Health Organization. 2006a. Public health, innovation and intellectual property rights (Report of the Commission on Intellectual Property Rights, Innovation and Public Health), (April). Geneva, Switzerland.
72. World Health Organization. 2006b. The selection and use of essential medicines: report of the WHO expert committee (including the 14th model list of essential medicines). WHO Technical Report No. 933. Geneva, Switzerland.
73. World Health Organization. 2007. Public health, innovation, and intellectual property: progress made by the intergovern-mental working group (Report by the Secretariat: A60/27) 5 April. Geneva, Switzerland.
74. World Intellectual Property Organization. 2004. Member states agree to further examine proposal on development. Press Release, No. 396, 4 October. Geneva, Switzerland.
75. World Intellectual Property Organization. 2007. Member states make significant headway in working on a WIPO development agenda. Press Release No. 478, 28 February. Geneva, Switzerland.
76. World Trade Organization. 1994. Agreement on trade-related aspects of intellectual property rights (15 April). Final act embodying the results of the Uruguay round of multilateral trade negotiations, legal instruments - Results of the Uruguay round, annex 1C, Vol. 21, 33 I.L.M. 1197.
77. World Trade Organization. 2001. Declaration on the TRIPS agreement and public health. WTO Doc WT/MIN(01)/ DEC//2, 14 November.
78. World Trade Organization. 2003. Implementation of paragraph 6 of the Doha declaration on theTRIPS agreement and pub-lic health.WTO Document IP/C/W/405, 30August. http://www.wto.org/English/tratop_e/trips_e/implem_para6_e.htm (accessed 15 June 2007).
79. World Trade Organization. 2007. Members OK amendment to make health flexibility permanent. Press Release, No. 426, 6 December. Geneva, Switzerland.